ACP
GYRE icon

Acuta Capital Partners’s Gyre Therapeutics GYRE Stock Holding History

Acuta Capital Partners’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-48,667
Closed -$1.5M – 45
2021
Q3 		$1.5M Sell
48,667
-42,666
-47% -$1.4M 0.53% 38
2021
Q2 		$2.97M Sell
91,333
-33,934
-27% -$1.16M 1.19% 29
2021
Q1 		$4.74M Sell
125,267
-55,733
-31% -$2.55M 1.71% 27
2020
Q4 		$8.57M Sell
181,000
-18,720
-9% -$811K 2.33% 17
2020
Q3 		$6.44M Hold
199,720
– – 1.75% 22
2020
Q2 		$8.79M Buy
199,720
+15,107
+8% +$709K 2.54% 13
2020
Q1 		$6.05M Buy
+184,613
New +$8.48M 2.93% 13
2018
Q3 		– Sell
-110,667
Closed -$9.69M – 38
2018
Q2 		$9.69M Sell
110,667
-43,296
-28% -$7.59M 1.72% 15
2018
Q1 		$29.8M Buy
153,963
+93,963
+157% +$17.5M 4.87% 8
2017
Q4 		$6.14M Buy
+60,000
New +$3.06M 1.16% 16

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Acuta Capital Partners's GYRE Position: Q4 2021 in Review

Acuta Capital Partners sold out of Gyre Therapeutics (GYRE) in Q4 2021, closing a stake of 48,667 shares — an estimated $1.5M sold.

Acuta Capital Partners first reported a position in GYRE in Q4 2017 and held it in 10 quarters. The position peaked at $29.8M in Q1 2018. 51 funds tracked by Wall St. Rank hold GYRE as of Q4 2021.

  • Acuta Capital Partners reported no remaining Gyre Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Acuta Capital Partners sold 48,667 Gyre Therapeutics shares in Q4 2021, an estimated $1.5M.
  • Acuta Capital Partners first reported a position in Gyre Therapeutics in Q4 2017 and held it in 10 quarters.
  • Acuta Capital Partners's Gyre Therapeutics position peaked at $29.8M in Q1 2018.
  • 51 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2021.

Based on Acuta Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.